Rheumatology International

, Volume 30, Issue 11, pp 1417–1427 | Cite as

Fibromyalgia and nutrition, what do we know?

  • Laura-Isabel Arranz
  • Miguel-Ángel Canela
  • Magda Rafecas
Review

Abstract

Many people suffer from fibromyalgia (FM) without an effective treatment. They do not have a good quality of life and cannot maintain normal daily activity. Among the different hypotheses for its ethiopathophysiology, oxidative stress is one of the possibilities. Non-scientific information addressed to patients regarding the benefits of nutrition is widely available, and they are used to trying non-evidenced strategies. The aim of this paper is to find out what we know right now from scientific studies regarding fibromyalgia disease and nutritional status, diets and food supplements. A systematic search has been performed on Medline with a wide range of terms about these nutritional issues. The search has been made during 2009, for articles published between 1998 and 2008. Target population: people suffering from FM. Vegetarian diets could have some beneficial effects probably due to the increase in antioxidant intake. There is a high prevalence of obesity and overweight in patients, and weight control seems to be an effective tool to improve the symptoms. Some nutritional deficiencies have been described, it is not clear whether they are directly related to this disease or not. About the usefulness of some food supplements we found very little data, and it seems that more studies are needed to prove which ones could be of help. Dietary advice is necessary to these patients to improve their diets and maintain normal weight. It would be interesting to investigate more in the field of nutrition and FM to reveal any possible relationships.

Keywords

Fibromyalgia Nutrition Diet Antioxidants Nutritional supplementation 

References

  1. 1.
    Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 33:160–172CrossRefPubMedGoogle Scholar
  2. 2.
    Weir P, Harlan G, Nkoy F et al (2006) The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th revision codes. J Clin Rheumatol 12:124–128CrossRefPubMedGoogle Scholar
  3. 3.
    Maquet D, Croisier JL, Crielaard JM (2000) Fibromyalgia in the year. Rev Med Liege 55(11):991–997PubMedGoogle Scholar
  4. 4.
    Lawrence R, Helmick C, Arnett F et al (1998) Estimates of the prevalence of artritis and selected músculoskeletal disorders in the United States. Artritis Rheum 41:778–799CrossRefGoogle Scholar
  5. 5.
    Wolfe F, Ross K, Anderson J et al (1995) The prevalence and characteristics of fibromyalgia in the general population. Artritis Rheum 38:19–28CrossRefGoogle Scholar
  6. 6.
    White KP, Speedchley M, Harth M et al (1999) The London fibromyalgia epidemiology study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 26(7):1570–1576PubMedGoogle Scholar
  7. 7.
    White KP, Harth M (2001) Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 5(4):320–329CrossRefPubMedGoogle Scholar
  8. 8.
    Valverde M, Juan A, Ribas B et al (2000) Prevalencia de la fibromialgia en la población española. Estudio EPISER 2000. Rev Esp Reumatol 27(5):157Google Scholar
  9. 9.
    Carmona L, Ballina J, Gabriel R et al (2001) EPISER study group. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60(11):1040–1045Google Scholar
  10. 10.
    Mas AJ, Carmona L, Valverde M et al (2008) EPISER study group. Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population results from a nationwide study in Spain. Clin Exp Rheumatol 26(4):519–526Google Scholar
  11. 11.
    Gamero F, Gabriel R, Carbonell J et al (2005) Pain in Spanish rheumatology outpatient offices: EPIDOR epidemiological study. Rev Clin Esp 205:157–163CrossRefGoogle Scholar
  12. 12.
    Salaffi F, De Angelis R, Gras W et al (2005) Pain prevalence, investigation group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 23(6):819–828Google Scholar
  13. 13.
    Bannwarth B, Blotman F, Roué-Le Lay K et al (2008) Fibromyalgia síndrome in the general population of France: a prevalence study. Joint Bone Spine 24. [Epub ahead of print]Google Scholar
  14. 14.
    Felson DT (2008) Comparing the prevalence of rheumatic diseases in China with the rest of the world. Editorial. Arthritis Res Ther 10:106Google Scholar
  15. 15.
    Eisinger J, Plantamura A, Marie PA et al (1994) Selenium and magnesium status in fibromyalgia. Magnes Res 7(3–4):285–288PubMedGoogle Scholar
  16. 16.
    Reinhard P, Schweinsberg F, Wernet D et al (1998) Selenium status in fibromyalgia. Toxicol Lett 96–97:177–180CrossRefPubMedGoogle Scholar
  17. 17.
    Ozgocmen S, Ozyurt H, Sogut S et al (2006) Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia etiologic and therapeutic concerns. Rheumatol Int 26:598–603CrossRefPubMedGoogle Scholar
  18. 18.
    Bagis S, Tamer L, Sahin G et al (2005) Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Reumatol Int 25:188–190CrossRefGoogle Scholar
  19. 19.
    Altindag O, Celik H (2006) Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox Rep 11(3):131–135CrossRefPubMedGoogle Scholar
  20. 20.
    Pieczenik SR, Neustadt J (2007) Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 83:84–92CrossRefPubMedGoogle Scholar
  21. 21.
    Ozgocmen S, Ozyurt H, Sogut S et al (2006) Current concepts in the pathophysilogy of fibromyalgia: the potential role of oxidative stress and nitric oxide. Reumatol Int 26:585–597CrossRefGoogle Scholar
  22. 22.
    Pall ML (2001) Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Med Hypotheses 57(2):139–145CrossRefPubMedGoogle Scholar
  23. 23.
    Hänninen O, Kaartinen K, Rauma AL et al (2000) Antioxidants in vegan diet and rheumatic disorders. Toxicology 155:45–53CrossRefPubMedGoogle Scholar
  24. 24.
    Donaldson MS, Speight N, Loomis S (2001) Fibromyalgia syndrome improved using a mostly raw vegetarian diet: an observational study. BMC Complement Altern Med 1:7CrossRefPubMedGoogle Scholar
  25. 25.
    Vecchiet J, Cipollone F, Falasca K et al (2003) Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 335(3):151–154CrossRefPubMedGoogle Scholar
  26. 26.
    Kennedy G, Spence VA, McLaren M et al (2005) Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med 39:584–589CrossRefPubMedGoogle Scholar
  27. 27.
    Richards RS, Wang L, Jelinek H (2007) Erythrocyte oxidative damage in chronic fatigue syndrome. Arch Med Res 38:94–98CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang Z, Cherryholmes G, Mao A et al (2008) High plasma levels of MCP-1 and Eotaxin provide evidence for an immunological basis of fibromyalgia. Exp Biol Med 2333:1171–1180Google Scholar
  29. 29.
    Wallace DJ, Linker-Israeli M, Hallegua D et al (2001) Cytokines paly an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 40:74–749CrossRefGoogle Scholar
  30. 30.
    Wallace DJ (2006) Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 12(1):17–22CrossRefPubMedGoogle Scholar
  31. 31.
    Chakrabarty S, Zoorob R (2007) Fibromyalgia. Am Fam Physician 15; 76(2):247–254Google Scholar
  32. 32.
    Carville SF, Arendt-Nielsen S, Bliddal H et al (2008) EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 67:536–541CrossRefPubMedGoogle Scholar
  33. 33.
    Perrot S, Dickenson AH, Bennett RM (2008) Fibromyalgia: harmonizing science with clinical practice considerations. Pain Practice 8(3):177–189CrossRefPubMedGoogle Scholar
  34. 34.
    Abeles M, Solitar BM, Pillinger MH et al (2008) Update on fibromyalgia therapy. Am J Med 121:555–561CrossRefPubMedGoogle Scholar
  35. 35.
    Goldenberg DL, Burckhardt C, Crofford L (2004) Management of fibromyalgia síndrome. JAMA 292(19):2388–2395CrossRefPubMedGoogle Scholar
  36. 36.
    Nishishinya MB, Rivera J, Alegre C et al (2006) Intervenciones no farmacológicas y tratamientos alternativos en la fibromialgia. Med Clin 12(8):295–299Google Scholar
  37. 37.
    Kaartinen K, Lami K, Hypen M et al (2000) Vegan diet alleviates fibromyalgia symptoms. Scand J Rheumatol 29(5):308–313CrossRefPubMedGoogle Scholar
  38. 38.
    Bennet RM (2002) A raw vegetarian diet for patients with fibromyalgia. Curr Rheumatol Rep 4(4):284Google Scholar
  39. 39.
    Azad KA, Alam MN, Hag SA et al (2000) Vegetarian diet en the treatment of fibromyalgia. Bangladesh Med Res Counc Bull 26(2):41–47PubMedGoogle Scholar
  40. 40.
    Michalsen A, Riegert M, Lüdtke R et al (2005) Mediterranean diet or extended fasting’s influence on changing the intestinal microflora, immunoglobulin A secretion and clinical outcome in patients with rheumatoid artritis and fibromyalgia: an observational study. BMC Complement Altern Med 5:22CrossRefPubMedGoogle Scholar
  41. 41.
    Smith JD, Terpening CM, Schmidt SOF et al (2001) Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 35:702–706CrossRefPubMedGoogle Scholar
  42. 42.
    Geenen R, Janssens EL, Jacobs JWG et al (2004) Dietary glutamate will not affect pain in fibromyalgia. J Rheumatol 31:785–787PubMedGoogle Scholar
  43. 43.
    Cairns BE, Svensson P (2005) Dietary glutamate and fibromyalgia. J Rheumatol 32(2):392–393; Author reply 393–394Google Scholar
  44. 44.
    Cymet TC (2003) A practical approach to fibromyalgia. J Natl Med Assoc 95:278–285PubMedGoogle Scholar
  45. 45.
    Arnold LM, Hudson JI, Keck PE et al (2006) Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 67:1219–1225CrossRefPubMedGoogle Scholar
  46. 46.
    Javaras KN, Harrison GP, Lalonde JK et al (2008) Co-occurrence of binge eating disorder with psychiatric and medical disorders. J Clin Psychiatry 69:266–273CrossRefPubMedGoogle Scholar
  47. 47.
    Bennett RM, Jones J, Turk DC et al (2007) An internet survey of 2, 596 people with fibromyalgia. BMC Musculoskeletal Disorders 8:27CrossRefPubMedGoogle Scholar
  48. 48.
    Patucchi E, Fatati G, Puxeddu A et al (2003) Prevalence of fibromyalgia in diabetes mellitus and obesity. Recent Prog Med 94:163–165Google Scholar
  49. 49.
    Yunus MB, Arslan S, Aldag JC (2002) Relationship between body mass index and fibromyalgia features. Scand J Rheumatol 31:27–31CrossRefPubMedGoogle Scholar
  50. 50.
    Mengshoel AM, Haugen M (2001) Health status in fibromyalgia–a followup study. J Rheumatol 28:2085–2089PubMedGoogle Scholar
  51. 51.
    Shapiro JR, Anderson DA, Noff-Burg S (2005) A pilot study of the effects of behavioral weight loss treatment on fibromyalgia symptoms. J Psychosom Res 59:275–282CrossRefPubMedGoogle Scholar
  52. 52.
    Neumann L, Lerner E, Glazer Y et al (2008) A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients. Clin Rheumatol 27(12):1543–1547CrossRefPubMedGoogle Scholar
  53. 53.
    Shaver JLF, Wilbur J, Robinson P et al (2006) Women’s health issues with Fibromyalgia syndrome. J Women’s Health 9(15):1035–1045Google Scholar
  54. 54.
    Hooper MM, Stellato TA, Hallowell PT et al (2007) Musculoskeletal findings in obese subjects before and after weight loss following bariatric surgery. Int J Obes 31:114–120CrossRefGoogle Scholar
  55. 55.
    Ananda A, Caterson I, Sambrook P et al (2008) The impact of obesity on the musculoskeletal system. Int J Obes 32(2):211–222CrossRefGoogle Scholar
  56. 56.
    Lowe JC, Yellin J, Honeyman-Lowe G (2006) Female fibromyalgia patients: lower resting metabolic rates than matched healthy controls. Med Sci Monit 12(7):CR282-9Google Scholar
  57. 57.
    Loevinger B, Muller D, Alonso C et al (2007) Metabolic syndrome in women with chronic pain. Metab Clin Exp 56:87–93PubMedGoogle Scholar
  58. 58.
    Verheesen RH, Schweitzer CM (2008) Iodine deficiency, more than cretinism and goiter. Med Hypotheses 71:645–648CrossRefPubMedGoogle Scholar
  59. 59.
    Pamuk GE, Pamuk ON, Set T et al (2008) An increased prevalence of fibromyalgia in iron deficiency anemia and thalassemia minor and associated factors. Clin Rheumatol 27:1103–1108CrossRefPubMedGoogle Scholar
  60. 60.
    Swezey RL, Adams J (1999) Fibromyalgia: a risk factor for osteoporosis. J Rheumatol 26(12):2642–2644PubMedGoogle Scholar
  61. 61.
    Al-Allaf AW, Mole PA, Paterson CR et al (2003) Bone health in patients with fibromyalgia. Rheumatology 42:1202–1206CrossRefPubMedGoogle Scholar
  62. 62.
    Plotnikoff GA, Quigley JM (2003) Prevalence of severe hipovitaminosis D in patients with persistent nonspecific musculoskeletal pain. Mayo Clin Proc 78:1463–1470CrossRefPubMedGoogle Scholar
  63. 63.
    Block SR (2004) Vitamin D deficiency is not associated with nonspecific musculoskeletal pain syndromes including fibromyalgia. Mayo Clin Proc 79(12):1585–1591CrossRefPubMedGoogle Scholar
  64. 64.
    Warner AE, Arnspiger SA (2008) Diffuse musculoskeletal pain is not associated with low vitamin D levels or improved by treatment with vitamin D. J Clin Rheumatol 14(1):12–16CrossRefPubMedGoogle Scholar
  65. 65.
    Armstrong DJ, Meenagh GK, Bickle I (2007) Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. Clin Rheumatol 26:551–554CrossRefPubMedGoogle Scholar
  66. 66.
    Mouyis M, Ostor AJK, Crisp AJ et al (2008) Hypovitaminosis D among rheumatology outpatients in clinical practice. Rheumatology 47:1348–1351CrossRefPubMedGoogle Scholar
  67. 67.
    Sendur OF, Tastaba E, Turan Y et al (2008) The relationship between serum trace elements levels and clinical parameters in patients with fibromyalgia. Rheumatol Int 28:1117–1121CrossRefPubMedGoogle Scholar
  68. 68.
    Rosborg I, Hyllén E, Lidbeck J et al (2007) Trace element pattern in patients with fibromyalgia. Sci Total Environ 385:20–27CrossRefPubMedGoogle Scholar
  69. 69.
    Eisinger J, Plantamura A, Marie PA et al (1994) Selenium and magnesium status in fibromyalgia. Magnes Res 7(3–4)–285–288Google Scholar
  70. 70.
    Schwarz MJ, Offenbaecher M, Neumeister A et al (2002) Evidence for an altered tryptophan metabolism in fibromyalgia. Neurobiol Dis 11:434–442CrossRefPubMedGoogle Scholar
  71. 71.
    Torpy DJ, Papanicolaou DA, Lotsikas AJ et al (2000) Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6. A pilot study in fibromyalgia. Arthritis and Rheumatism 43(4):872–880Google Scholar
  72. 72.
    Maes M, Verkerk R, Delmeire L et al (2000) Serotoninergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia. Psychiatry Res 97:11–20CrossRefPubMedGoogle Scholar
  73. 73.
    Rohr UD, Herold J (2002) Melatonin deficiencies in women. Maturitas 41(1):S85–S104CrossRefPubMedGoogle Scholar
  74. 74.
    Caruso I, Puttini PS, Cazzola M et al (1990) Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 18:201–209PubMedGoogle Scholar
  75. 75.
    Puttini PS, Caruso I (1992) Primary fibromyalgia syndrome and 5-HTP: a 90-day open study. J Int Med Res 20:182–189Google Scholar
  76. 76.
    Nicolodi M, Sicuteri F (1996) Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis therapy. Adv Exp Med Biol 398:373–379PubMedGoogle Scholar
  77. 77.
    Birdsall TC (1998) 5-Hydroxytriptohan: a clinically-effective serotonine precursor. Altern Med Rev 3(4):271–280PubMedGoogle Scholar
  78. 78.
    Merchant RE, Carmack CA, Wise CM (2000) Nutritional supplementation with chlorella pyrenoidosa for patients with fibromyalgia syndrome: a pilot study. Phytother Res 14:167–173CrossRefPubMedGoogle Scholar
  79. 79.
    Merchant RE, Andre CA, Wise CM (2001) Nutritional supplementation with chlorella pyrenoidosa for fibromyalgia syndrome: a double-blind, placebo-controlled, crossover study. J Musculoskelet Pain 9(4)Google Scholar
  80. 80.
    Merchant RE, Andre CA (2001) A review of recent clinical trials of the nutritional supplement chlorella pyrenoidosa in the treatment of fibromyalgia, hypertension, and ulcerative colitis. Altern Ther Health Med 7(3):79–91PubMedGoogle Scholar
  81. 81.
    Rossini M, Di Munno O, Valentini G et al (2007) Double-blind, multicenter trial comparing acetyl-l-carnitine with placebo in the treatment of fibomyalgia patients. Clin Exp Rheumatol 25(2):182–188PubMedGoogle Scholar
  82. 82.
    Lister RE (2002) An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo Biloba extract in Fibromyalgia Syndrome. J Inter Med Res 30:195–199Google Scholar
  83. 83.
    Olson GB, Savage S, Olson J (2000) The effects of collagen hydrolysat on symptoms of chronic fibromyalgia and temporomandibular joint pain. Cranio 18(2):135–141PubMedGoogle Scholar
  84. 84.
    Bramwell B, Ferguson S, Scarlett N et al (2000) The use of ascorbigen in the treatment of fibromyalgia patients: a preliminary trial. Altern Med Rev 5(5):455–462PubMedGoogle Scholar
  85. 85.
    Jacobsen S, Danneskiold-Samsoe B, Andersen RB (1991) Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 20(4):294–302Google Scholar
  86. 86.
    Fetrow CW, Avila JR (2001) Efficacy of the dietary supplement S-adenosyl-L-methionine. Ann Pharmacother 35:1414–1425CrossRefPubMedGoogle Scholar
  87. 87.
    Dykman KD, Tone C, Ford C et al (1998) The effects of nutritional supplements on the symptoms of fibromyalgia and chronic fatigue syndrome. Integr Physiol Behav Sci 33(1):61–71Google Scholar
  88. 88.
    Werbach MR (2000) Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev 5(2):93–108PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Laura-Isabel Arranz
    • 1
  • Miguel-Ángel Canela
    • 2
  • Magda Rafecas
    • 3
  1. 1.Faculty of PharmacyUniversity of BarcelonaBarcelonaSpain
  2. 2.Department of Managerial Decision Sciences, IESE Business SchoolBarcelonaSpain
  3. 3.Department of Nutrition and Food Science, Faculty of PharmacyUniversity of BarcelonaBarcelonaSpain

Personalised recommendations